Delivery Order SPE2DR25D9316-SPE2DR26FSCB1

The Defense Logistics Agency issued a delivery order valued at $27,248.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Cerezyme 400 unit vials. This firm fixed-price delivery order was awarded on December 8, 2025, with an ultimate completion date of December 30, 2025, and was issued without set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that positions the company as a regional prime vendor contractor serving Department of Defense healthcare operations globally.

DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with delivery orders ranging from minimal purchases to awards exceeding $115,000. The company's comprehensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables distributed primarily to military healthcare facilities worldwide. The underlying PPV-G GEN V prime vendor contract, designated SPE2DR and valued at up to $499,999,999, extends through December 31, 2036, with a 30-month base period and three 30-month option periods, establishing DMS Pharmaceutical Group as a key contributor to sustained Department of Defense pharmaceutical supply operations.